Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Resveratrol in Type2 Diabetes and Obesity

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2012 by Kaleida Health.
Recruitment status was:  Active, not recruiting
Information provided by (Responsible Party):
Paresh Dandona, MD, Kaleida Health Identifier:
First received: July 7, 2010
Last updated: December 17, 2012
Last verified: December 2012
The main objective of this study is to investigate the effect of resveratrol on inflammatory mediators and insulin resistance at the cellular and molecular level in obese non diabetic and type 2 diabetic subjects in vivo. This research will investigate the hypothesis that resveratrol, when given orally to obese and type 2 diabetic subjects induces a decrease in reactive oxygen species (ROS) generation and the pro-inflammatory transcription factor nuclear factor-kB (NF-kB) and the inflammatory mediators regulated by it. The hypothesis that resveratrol suppresses the high fat, high carbohydrate (HFHC) meal induced inflammatory and oxidative response, will also be investigated. This research will also investigate the hypothesis that resveratrol intake for 12 weeks improves insulin sensitivity by lowering the Homeostasis model assessment of insulin resistance (HOMA-IR), an index of insulin resistance and, that resveratrol intake will cause an increase in incretins.

Condition Intervention Phase
Type 2 Diabetes
Insulin Resistance
Drug: Placebo
Drug: Resveratrol 40 mg oral three times a day
Drug: Resveratrol 500 mg oral once daily.
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Participant)
Primary Purpose: Treatment
Official Title: Effect of Resveratrol on Insulin Resistance and Inflammatory Mediators in Obese and Type 2 Diabetic Subjects

Resource links provided by NLM:

Further study details as provided by Kaleida Health:

Primary Outcome Measures:
  • NF-Kb [ Time Frame: 12 weeks ]
    To investigate the effect of resveratrol on ROS generation and the pro-inflammatory transcription factor NF-kB

Secondary Outcome Measures:
  • GLP-1 [ Time Frame: 12 weeks ]
    To see whether Resveratrol leads to a greater stimulation of the incretin system and secretion/release of GIP and GLP-1 when compared to that following placebo

Estimated Enrollment: 102
Study Start Date: December 2008
Estimated Study Completion Date: August 2014
Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Placebo tablets
Drug: Placebo
Experimental: Resveratrol 40 mg oral three times a day
Drug: Resveratrol 40 mg oral three times a day
Experimental: resveratrol 500 mg oral once daily.
Drug: Resveratrol 500 mg oral once daily.
Resveratrol 500 mg oral once daily.


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. 20 years of age and older
  2. Healthy Obese subjects with BMI > 30
  3. Type 2 Diabetics with BMI > 30
  4. Subjects with good peripheral vein.
  5. Subjects on statins, ACE inhibitors and thiazolidenediones will be allowed as long as they are on stable doses of these compounds and the dosage is not changed during the course of study.

Exclusion Criteria:

  1. Subjects on any antioxidant medication
  2. Patient on non-steroidal anti-inflammatory drug
  3. On any agent with significant antioxidant properties.
  4. History of drug or alcohol abuse
  5. Any life threatening disease
  6. Allergy to peanuts, grapes, wine, mulberries.
  7. Pregnant women.
  8. Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass surgery or coronary angioplasty) in the previous four weeks.
  9. Subjects on anticoagulants.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01158417

United States, New York
115 Flint Road
Buffalo, New York, United States, 14221
Sponsors and Collaborators
Kaleida Health
Principal Investigator: Paresh Dandona, MD Kaleida Health
  More Information

Additional Information:
Responsible Party: Paresh Dandona, MD, MD, Kaleida Health Identifier: NCT01158417     History of Changes
Other Study ID Numbers: 1935
Study First Received: July 7, 2010
Last Updated: December 17, 2012

Keywords provided by Kaleida Health:
Type 2 Diabetes
Insulin Resistance

Additional relevant MeSH terms:
Diabetes Mellitus, Type 2
Insulin Resistance
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Nutrition Disorders
Body Weight
Signs and Symptoms
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents
Enzyme Inhibitors
Platelet Aggregation Inhibitors
Antimutagenic Agents processed this record on May 23, 2017